CereScan, Corp. Competitors

A global healthcare technology leader — boldly attacking the most challenging health problems facing humanity with innovations that transform lives.

BrainCheck is a digital health company powering positive progress in cognitive health. The BrainCheck Platform™ offers the most comprehensive digital cognitive toolset to promote proactive screening, detect early signs of decline, and personalize care planning – anytime, anywhere. Founded by renowned neuroscientists and technologists, including David Eagleman, PhD, our intuitive solutions transcend the limitations of traditional methods and expand access to cognitive care with the tap of a finger, from any device, in any location. Trusted by hundreds of leading providers and healthcare systems, our clinically-validated digital cognitive assessment and care planning tools fit seamlessly into workflows, including EHR integration, delivering actionable insights with ease. Earlier, better, longer brain health begins with empowering action: Don’t raincheck the BrainCheck™. To learn more, visit braincheck.com.

Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine. Positron's Attrius® PET and NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine. Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co a subsidiary of Neusoft Medical Systems. Positron was founded in 1983 and is based in Niagara Falls, NY.